Bioprocess Webinars

Cell and gene therapies are rapidly advancing and with that, the need to effectively generate large volumes of viable cell and gene therapy products to fuel the pipeline. In this fast-paced industry, researchers, manufacturers, life science companies, and academics are working together to solve the significant challenges. Join Corning and Expression Therapeutics in a discussion about their experiences transitioning from R&D to upstream manufacturing for gene therapies: navigating many variables and overcoming obstacles to innovate the process and make novel gene therapies a reality.

This discussion will cover:
- Key challenges and considerations for moving gene therapies into clinical trials
- How to overcome challenges in manufacturing with creative thinking to push technologies forward
- How industry partnerships are evolving and how you can leverage them to drive innovation

Roundtable Guests:
William Swaney, M.S., President, Expression Manufacturing LLC
Gabriela Denning, Ph.D., Vice President of Research & Development, Expression Therapeutics
Anindya Dasgupta, Ph.D., Director GMP Manufacturing, Expression Manufacturing LLC

Advances in the science of gene and cell therapies have created rapid growth in the industry, with the common challenge of producing therapeutic cells or viruses at manufacturing scale. Corning has developed a novel fixed bed bioreactor system to address the need for more efficient solutions for cell and gene therapies as well as vaccine production.
In this webinar you will learn how the Corning Ascent FBR System enables high yields of cells and viral vectors through its unique fixed bed design. Further, we will cover how efficient cell-harvest, automation, process control and ready-to-use consumables will improve your adherent bioproduction.

Novel gene therapies are entering the clinic and generating clinical data readouts at an unprecedented rate. As with any new therapy, the key readouts are safety and efficacy. While there has been substantial progress and clinical success, the gene therapy field must continue to refine the engineering of viral vectors for increased manufacturability, targeted efficacy, and safety.

Exclusively designed for experts working in the Gene Therapy space, this exclusive 1-hour symposium will allow you to:
-Get up to speed with AI and Machine learning for vector engineering and how it can optimize viral vectors
-Discover how to enhance therapeutic efficacy with targeted tissue and cell expression
-Delve into the impact of transgene cassette optimization to understand the next generation of viral vector manufacturing

The cell and gene therapy field is rapidly advancing, placing a focus on manufacturing challenges to meet the growing demand. The efficient harvest of viable cells or cell products and maintenance of native biological function influences platform and workflow choices. Established protocols for viral vector production on a range of scalable adherent platforms can be tailored to meet end objectives, taking into consideration factors such as desired yield, time to optimize the process, facility space, and media usage. Essentially, there is no ‘one-size-fits-all’ platform for upstream adherent cell culture.

In this Expert Roundtable discussion, three experts speak about the challenges the rapidly expanding gene therapy field is facing in scaling up adeno-associated vector manufacturing, and the potential solutions.

Charlotte Barker, Editor, BioInsights, speaks to William Swaney, President of Manufacturing, Expression Therapeutics, John (Yoshi) Shyu, Director, Global Scientific Applications, Corning Life Sciences, and Nikhil Tyagi, Director of Cell Therapy Process Development, Center for Breakthrough Medicines

Cell therapies offer a promising approach to treat severe and rare diseases. However, sustained manufacturing of cell therapy products is at risk due to the high costs associated with manufacturing variability and safety assessments. One significant risk in the manufacturing process is contamination of product, which can contribute to millions of dollars in added cost. In this webinar, we will address how integrating closed system approaches during process development or manufacturing can mitigate contamination risk and associated costs.

This webinar will introduce viewers to Corning’s closed system solutions, with attention to the following topics:

Assembly and customization of closed systems
Closed system process considerations and flexibility in design
Scaling up and out using closed systems
Attend this webinar to learn more about:

Benefits of closed systems
Assessing risk of contamination
Key considerations for closed system design

Please join us for a free webinar hosted by Pharma's Almanac and sponsored by Corning Life Sciences, "Designing a Recipe for Stem Cell Therapy Success" on Tuesday, December 05, 2023 at 11:00 A.M. EST.

We are excited to feature two Field Application Scientists from Corning Life Sciences: Ben Josey, Ph.D., and Robert Padilla, MS.

This webinar will be moderated by David Alvaro, Ph.D., of Pharma's Almanac and will include a live Q&A portion for participants to ask their own questions.

We will discuss considerations and strategies for transitioning stem cell therapies from research into a production environment.

In this free webinar, we will cover:
• Cell type and end-product goals
• Platform and media selection for cell expansion
• Surface chemistry substrate choices and other cell culture success factors
• Succesfully translating your biology as you scale
• De-risking and optimizing processes
• And other biological and operational considerations